Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by equities researchers at BMO Capital Markets in a research report issued to clients and investors on Wednesday, January 3rd.

Other equities analysts also recently issued reports about the company. Leerink Swann raised their price objective on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a report on Thursday, October 19th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Berenberg Bank restated a “buy” rating and issued a $96.00 price objective (up from $86.00) on shares of Gilead Sciences in a report on Wednesday, September 6th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, October 19th. Finally, Mizuho raised their target price on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and seventeen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $85.58.

How to Become a New Pot Stock Millionaire

Shares of Gilead Sciences (GILD) opened at $88.80 on Wednesday. The stock has a market capitalization of $115,970.00, a PE ratio of 10.10, a price-to-earnings-growth ratio of -1.89 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $89.54.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period last year, the business posted $2.75 EPS. equities analysts predict that Gilead Sciences will post 8.53 earnings per share for the current year.

In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the transaction, the insider now owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 591,666 shares of company stock valued at $44,466,567. Insiders own 1.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in GILD. BlackRock Inc. raised its stake in shares of Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after buying an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Gilead Sciences by 1.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after buying an additional 310,607 shares in the last quarter. FMR LLC raised its stake in shares of Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares in the last quarter. Institutional investors and hedge funds own 76.11% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences (NASDAQ:GILD) Earns Hold Rating from BMO Capital Markets” was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.mareainformativa.com/2018/01/30/gilead-sciences-gild-earns-hold-rating-from-bmo-capital-markets-updated-updated-updated.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.